AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M

AbbVie, already a leader in the T cell engager field with Epkinly and a Phase 3 program, is further digging into the field with a new discovery collaboration with EvolveImmune Therapeutics. The Chicago pharmaceutical company ...